National Bowel Cancer Audit: The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit – Healthcare Quality Improvement Partnership

A feasibility study linking the NHS England National Cancer PROM’s to the National Bowel Cancer Audit (NBOCA) data to establish the feasibility of the PROMs as part of the national clinical audit. This was assessed according to: the characteristics of

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer: Technology appraisal guidance [TA536] – NICE

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults. Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults.

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine: Technology appraisal guidance [TA535] – NICE

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine. Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid

Review of the evidence in relation to the treatment criteria for Ibrutinib: Letter from Professor Peter Clark – NHS England

This letter, sent to Professor Stephen Powis, provides information about the re-examination of the commissioning treatment criteria for the use of ibrutinib in previously treated patients with chronic lymphocytic leukaemia (CLL).

Screening Quality Assurance Visit Report: NHS Bowel Cancer Screening Programme West London Bowel Cancer Screening Centre – Public Health England

The findings in this report relate to the quality assurance (QA) visit of West London Bowel Cancer Screening Programme held on 2 November 2017. Finds the West London bowel cancer screening programme is well supported by the director of screening

Screening Quality Assurance visit report: NHS Bowel Cancer Screening Programme Norfolk and Norwich – Public Health England

The findings in this report relate to the quality assurance visit of the Norfolk and Norwich screening service held on 15 November 2017. Finds this well-led and resilient bowel screening team is at the forefront of bowel screening in England. The enthusiastic

National Cancer Patient Experience Survey 2017: National Results Summary – Quality Health

Report that finds for patient experience overall ratings continue to improve, with year on year increases in reported positive experience. Patients also reported more positively on areas including involvement in decisions about care and treatment, and being treated with dignity

Living With and Beyond Cancer – Baseline Activity January – March 2017 – NHS England

This report sets out baseline activity data from January to March 2017 for Stratified Follow Up and Recovery Package interventions. This is the first time national data of this type has been reported.

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: Technology appraisal guidance [TA531] – NICE

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults. This guidance replaces NICE technology appraisal guidance 447.

Early and locally advanced breast cancer: diagnosis and management: NICE guideline [NG101] – NICE

This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person’s individual preferences. NICE has also produced guidelines on advanced breast cancer, familial breast

National Audit of Breast Cancer in Older Patients: 2018 Annual Report: Results of the Prospective Audit in England and Wales for women diagnosed between January 2014 and December 2016 – National Audit of Breast Cancer in Older Patient

Evaluates the quality of care provided to women aged 70 years or older by breast cancer services in England and Wales. The aim of the audit is to evaluate the care delivered to women from the point of initial diagnosis to

Advancing care, advancing years: improving cancer treatment and care for an ageing population – Cancer Research UK

Cancer UK report that notes that every year around 360,000 people in the UK were diagnosed with cancer in 2015. 36% of these people were 75 and over. By 2035, this proportion will rise to almost half (46%), because of the

Screening Quality Assurance visit report: NHS Breast Screening Programme Isle of Wight – Public Health England

The findings in this report relate to the quality assurance visit of the Isle of Wight screening service held on 21 November 2017. The unit consistently exceeds the national achievable standard for uptake of 70%. The overall uptake for the 50-70 age

Screening Quality Assurance visit report: NHS Cervical Screening Programme Bolton NHS Foundation Trust – Pulic Health England

The findings in this report relate to the quality assurance (QA) visits of the Bolton NHS Foundation Trust screening service held on 8 December 2016 and the 3 February 2017. The QA visit team identified 10 high priority findings as

Screening Quality Assurance visit report NHS Cervical Screening Programme: University Hospitals of South Manchester NHS Foundation Trust – Public Health England

The findings in this report relate to the quality assurance (QA) visit of the University Hospitals of South Manchester NHS Foundation Trust screening service held on 10 November 2016. The QA visit team identified one immediate concern. A letter was sent to

Screening Quality Assurance visit report: NHS Cervical Screening Programme Colchester Hospital University NHS Foundation Trust – Public Health England

The findings in this report relate to the quality assurance visit of the Colchester Hospital University NHS Foundation Trust (CHUFT) screening service held on 2 November 2017. The QA visit team identified 13 high priority findings as summarised below: there is

Rebuilding my body: Breast reconstruction in England – Breast Cancer Now

Research from Breast Cancer Now into the availability of breast reconstruction surgery, that finds some Clinical Commissioning Groups (CCGs) in England are restricting access to this surgery. Since 2012, 22.6% of CCGs have introduced official policies restricting breast reconstruction surgery while a further 4.3% have policies that are either informal

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma: Technology appraisal guidance [TA524] – NICE

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults. This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446.  

Arsenic trioxide for treating acute promyelocytic leukaemia: Technology appraisal guidance [TA526] – NICE

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.  

Midostaurin for untreated acute myeloid leukaemia: Technology appraisal guidance [TA523] – NICE

Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.